Skip to main content
Premium Trial:

Request an Annual Quote

Court Rules in Favor of Natera in CareDx Unfair Competition Claim, Voids Damages

This article has been updated to include information from a statement made by CareDx and to clarify that the court determined that although Natera engaged in willful deception, it could not be linked to customer reliance on said advertisments.

NEW YORK – The US District Court for the District of Delaware found Natera not guilty of unfair competition against CareDx and that CareDx is not entitled to damages related to that claim, according to court filings issued Monday.

The decision essentially reverses a verdict made last year concerning damages owed because of false advertising. In that ruling, a jury ordered Natera to pay CareDx $21.2 million in compensatory damages and $23.7 million in punitive damages.

Although the court let stand the jury's earlier finding that both companies engaged in some instances of false advertising, it determined that CareDx failed to link any false statement to customer reliance on that advertising. 

The court also ruled that CareDx failed to show that Natera's actions caused it injury. This, the court explained in a memorandum, made CareDx ineligible for damages under that claim.

In a statement made on Tuesday, CareDx stated that it intends to appeal the court's decision not to award monetary damages. 

In morning trading on the Nasdaq, Natera's shares were down about 1 percent at $48.83, while CareDx's shares were up a fraction of a percent at $10.17.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.